Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Paradigm Biopharmaceuticals and NFL Alumni Health Sign Partnership to Tackle Osteoarthritis in Ex-Players

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Paradigm Biopharmaceuticals Ltd (ASX: PAR) (Paradigm or the Company), a clinical-stage biopharmaceutical company focused on repurposing existing molecules for new indications with unmet clinical needs, is pleased to announce it has entered into a corporate partnership with NFL Alumni Health (NFLAH). This partnership will inform NFL Alumni Association (NFLAA) members about osteoarthritis disease onset and progression, and current treatment options and provide information about actively enrolling in clinical trials throughout the U.S.

The NFLAA has over 10,000 members and represents former NFL players, coaches, executives, spouses, cheerleaders, and associate members through its 40 chapters across the U.S. NFL Alumni Health is a wholly owned subsidiary of NFLAA offering informational resources, programs, services, and other benefits to NFLAA members and the general public. This division of the NFLAA appraises corporate partners that may provide beneficial research opportunities in health areas relevant to their members. NFL Alumni Health oversees the vetting process to ensure they bring credible and meaningful health sector-related partnerships to their membership. Paradigm’s designation as NFLAH’s newest corporate and research partner demonstrates its leading role in developing a safe and effective potential treatment for those suffering with OA.

Kyle Richardson, NFL Alumni Association Co-Director of Healthcare Initiatives, commented on the partnership: “The NFL Alumni Health division of the NFL Alumni Association is driven to provide initiatives that help its members learn more about and gain access to safe and effective treatments through clinical trials and other FDA-approved treatment options. In males under the age of 60, arthritis is over three times more prevalent in retired NFL players than in the general U.S. population. We are pleased to hear the positive experience several of our alumni members have had through working with Paradigm and we hope this partnership will inform a larger number of alumni on the disease of osteoarthritis and the available clinical trials that are currently enrolling participants.”

Paradigm previously submitted an IND application for an expanded access program protocol to treat 10 patients for osteoarthritis-associated knee pain with Zilosul®. The US FDA provided clearance for this program to proceed in September 2019. On 30th July 2020, Paradigm released the results of this EAP demonstrating that at week 12, the 10 participants treated with Zilosul® achieved an average WOMAC® pain reduction of 65%. Zilosul® was well tolerated in this program.

Paradigm remained in close contact with the EAP physician and participants, leading to an introduction to NFL Alumni Health. The NFL endorsed this partnership following a review of Paradigm’s clinical program results as well as the ongoing global registration clinical trial. Paradigm’s introduction from such an enthusiastic group within their own membership made Paradigm an ideal partnering candidate to present to their constituency.

Paradigm CEO, Marco Polizzi commented, “Having followed the progress of the expanded access program participants and hearing first-hand the positive impact Zilosul® has had on their lives. Paradigm is honored to be able to continue to work with NFL Alumni members to inform them of the onset and progression of osteoarthritis and Paradigm’s clinical progress through phase 3 as we strive to bring Zilosul® ® to commercialisation for the millions suffering from the debilitating effects of OA”.

Access EAP study results here:  https://paradigmbiopharma.com/performance-progress/#announcements

NFL Alumni Health: https://nflalumnihealth.org

Osteoarthritis is the most prevalent form of joint disease, affecting up to 16% of the population in the developed world, with more than 72 million people in the US, EU5, Canada, and Australia suffering from it1. OA has a significant impact on day-to-day functioning. Although the levels of pain and disability may fluctuate, it has no known cure or spontaneous remission and is associated with irreversible structural damage and progression over time.


Read other news of interest here.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine